Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06031688 · ClinicalTrials.gov registry record · Phase 2

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

A Phase 2 study of Stage IV Lung Cancer AJCC v8 and Recurrent Lung Non-Small Cell Carcinoma, sponsored by SWOG Cancer Research Network.

Recruiting
Registry status
Phase 2
Development phase
56
Enrollment target
20
Study locations

NCT06031688: Recruiting Phase 2 study of Stage IV Lung Cancer AJCC v8 and Recurrent Lung Non-Small Cell Carcinoma, sponsored by SWOG Cancer Research Network.

NCT06031688 is a Phase 2 study of Stage IV Lung Cancer AJCC v8 and Recurrent Lung Non-Small Cell Carcinoma that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 56 participants, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06031688, a Phase 2 study of Stage IV Lung Cancer AJCC v8 and Recurrent Lung Non-Small Cell Carcinoma, is actively recruiting participants, sponsored by SWOG Cancer Research Network.

RECRUITING
Registry status
Phase 2
Development phase
56 participants
Enrollment target
20
Study locations

Study Summary

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.

Primary Outcome

Rates will be compared using a chi-squared test at the 1-sided 10% level and also presented as the difference in response rates with the associated 80% confidence interval for the difference, Further, response rates and associated 80% confidence interval will be estimated for each arm.

Conditions Studied

Stage IV Lung Cancer AJCC v8 Recurrent Lung Non-Small Cell Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • BIOLOGICAL Ramucirumab
  • PROCEDURE Lymphoscintigraphy

Study Locations (20)

California

  • Kaiser Permanente-Anaheim - Anaheim
  • Sutter Auburn Faith Hospital - Auburn
  • Kaiser Permanente-Baldwin Park - Baldwin Park
  • Kaiser Permanente-Bellflower - Bellflower
  • Alta Bates Summit Medical Center-Herrick Campus - Berkeley
  • Tower Cancer Research Foundation - Beverly Hills
  • Kaiser Permanente-Fontana - Fontana
  • Palo Alto Medical Foundation-Fremont - Fremont
  • Kaiser Permanente South Bay - Harbor City
  • Kaiser Permanente-Irvine - Irvine
  • UC San Diego Moores Cancer Center - La Jolla
  • Kaiser Permanente Los Angeles Medical Center - Los Angeles
  • Kaiser Permanente West Los Angeles - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles

Alabama

  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis - Daphne
  • Thomas Hospital - Fairhope
  • Mobile Infirmary Medical Center - Mobile
  • Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland - Saraland

Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2024-08-08
Est. Completion 2028-05-31
Phase Phase 2
SWOG Cancer Research Network

270 total trials

What NCT06031688 shows while recruiting

NCT06031688 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (43% lower).

The record links to 2 conditions, with Stage IV Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06031688 names 20 study sites across 3 states, led by California, Alabama, Arkansas.

Frequently Asked Questions

What is clinical trial NCT06031688 about?

NCT06031688 is a clinical study titled "Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)". This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of...

What is the current status of trial NCT06031688?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2024-08-08. Estimated completion is 2028-05-31.

What conditions does trial NCT06031688 study?

This clinical trial studies the following conditions: Stage IV Lung Cancer AJCC v8, Recurrent Lung Non-Small Cell Carcinoma.

What interventions are being tested in trial NCT06031688?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Ramucirumab (BIOLOGICAL), Lymphoscintigraphy (PROCEDURE).

Who is sponsoring clinical trial NCT06031688?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06031688 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Lung Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06031688's enrollment target sits among peer trials

56 31st of 81 higher than 49 of 81 other Stage IV Lung Cancer AJCC v8 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage IV Lung Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02287428 · 56 participants · Phase 1

    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

  • NCT02923011 · 56 participants · Phase 3

    Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

  • NCT02935283 · 56 participants

    Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders

  • NCT03375866 · 56 participants · NA

    Effects of Mixed Nut Consumption on Satiety and Weight Management

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06031688

Source: ClinicalTrials.gov NCT06031688, the US trial registry maintained by the National Library of Medicine. NCT06031688 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.